Condition: Psychosis Associated With Alzheimer's Disease · Sponsor: MapLight Therapeutics
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
This description comes directly from the study's public registry record.
Clinical Trials Contact Center · +1 650 839 4380 · ML-007C-MA-ADP@maplightrx.com
Always discuss trial participation with your own doctor first.
| Clinical Site | Doral, Florida, United States | Recruiting |
| Clinical Site | Miami, Florida, United States | Recruiting |
| Clinical Site | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07459660